Poll: Many Americans say they will lose trust in public health recommendations under federal leadership changes
Reports and Proceedings
Updates every hour. Last Updated: 29-Oct-2025 18:11 ET (29-Oct-2025 22:11 GMT/UTC)
A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve throughout the different clinical phases of Hepatitis B virus (HBV) infection. Researchers analyzed liver and blood samples from patients in various clinical phases—acute hepatitis B (AHB), immune tolerant (IT), immune active (IA), and inactive chronic infection (ICI)—using single-cell RNA and TCR/BCR sequencing. The findings highlight critical immune cell subsets and potential molecular mechanisms that drive disease progression, providing valuable targets for the development of future immunomodulatory therapies.
In April 2025, the internationally renowned academic journal The Journal of the American Medical Association (JAMA) (Impact Factor: 63.5) published online a study titled “Non-Risk-Based Lung Cancer Screening With Low-Dose Computed Tomography”, led by Professors Jianxing He and Wenhua Liang from the First Affiliated Hospital of Guangzhou Medical University and the National Clinical Research Center for Respiratory Disease.
This research, focusing on lung cancer screening strategies, revealed that the non-risk-based (universal) screening approach - unrestricted by traditional high-risk criteria - achieved a comparable detection rate of lung cancer among individuals not classified as high-risk relative to those who were. The findings underscore the necessity of evaluating the effectiveness of lung cancer screening in non-high-risk populations and developing biomarker-based enrichment strategies to refine pre-screening selection in this subgroup.